Pharm-Olam International Has Been Acquired by Quad-C Management. This transaction closed on February 1, 2017. Pharm-Olam International is a leading clinical contract research organization (CRO) providing full-service solutions to help clients successfully manage and advance their clinical trials. Based in Houston, TX, and with offices worldwide, Pharm-Olam has a track record of supporting global clinical trials in more than 60 countries. Pharm-Olam has experience in all clinical phases with a focus on Phase II and Phase III global trials. Its expertise covers a wide range of therapeutic areas and major indications, addressing complex, high-growth areas such as oncology, infectious diseases, endocrinology, and orphan indications.Founded in 1989 and based in Charlottesville, Virginia, Quad-C is a middle-market private equity firm focused on investing in well-established business services, consumer, general industrial, healthcare, specialty distribution, and transportation and logistics companies. In its 25-year history, the company has invested over $2 billion of equity across more than 50 companies. The Quad-C team is committed to partnering with entrepreneurs and management teams to accelerate growth and create long-term value.
Market Pulse transactions shown herein are provided as a matter of public record. These transactions have been compiled from press releases, corporate announcements and other public sources to provide an overview of acquisition and merger activities within the healthcare and life sciences sectors.